4Kscore 7.5%切点用于前列腺穿刺决策:高敏感度与高阴性预测值
该研究合并美国两项前瞻性多中心试验共1378例患者数据,评估4Kscore 7.5%低风险切点作为前列腺穿刺指征的表现。结果该切点可减少32%穿刺,对GG≥2前列腺癌敏感度94%、阴性预测值95%,低风险组无GG≥4癌。
要点
- 4Kscore 7.5%切点可安全减少约32%前列腺穿刺。
- 该切点对GG≥2癌敏感度94%、阴性预测值95%。
- 低风险4Kscore组未发现GG≥4前列腺癌。
核心结论
- 4Kscore 7.5%切点可显著减少前列腺穿刺,同时对侵袭性前列腺癌保持高敏感度和阴性预测值。
研究设计与样本
- 合并分析美国两项前瞻性多中心试验,共纳入1378例患者。
- 在全体队列及45-75岁且总PSA 3.0-10.0 ng/mL、非洲裔和非非洲裔三个亚组中评估4Kscore 7.5%切点。
主要发现
- 以4Kscore 7.5%为穿刺决策阈值,穿刺量减少32%。
- 低风险4Kscore组共21例(4.8%)为ISUP GG 2或3级前列腺癌。
- 对GG≥2癌的敏感度为94%,阴性预测值为95%。
- 低风险4Kscore组未发现GG≥4前列腺癌。
- 各亚组分析结果相似。
关键数值与推荐
- 4Kscore切点7.5%用于决定是否进行前列腺穿刺。
- 对GG≥2前列腺癌敏感度94%,阴性预测值95%。
- 穿刺减少比例32%。
临床怎么用
- 对PSA升高患者可参考4Kscore 7.5%切点筛选低风险者,减少不必要穿刺。
- 低风险4Kscore结果可用于辅助排除高级别前列腺癌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the 4Kscore test's low risk cut-off of 7.5% as the indication to proceed with a prostate biopsy by combining data from 2 independent prospective multicentre trials in the United States which have validated the 4Kscore test as a continuous score to predict clinically significant prostate cancer. MATERIALS AND METHODS: We analyzed the data from 2 prospective multicenter trials in the United states to determine the number of men who could safely avoid a prostate biopsy and the presence of clinically significant cancers detected, at a 4Kscore cut-off of 7.5%. We evaluated this in the entire cohort, and 3 subgroups of men aged 45-75 years with a total prostate specific antigen between 3.0 and 10.0 ng/mL, African American, and non-African American men. RESULTS: The analysis included 1378 patients. The combination analysis at a 7.5% threshold to decide upon a prostate biopsy, was associated with a 32% biopsy reduction. A total of 21 men (4.8%) with a low risk 4Kscore had International society of Urological Pathology, prostate cancer Grade group (GG) 2 or 3 cancer, leading to a sensitivity of 94% for detecting GG ≥2 cancer, and a negative predictive value of 95%. There were no GG ≥4 cancers with a low risk 4Kscore. Analyses in various subgroups afforded similar results. CONCLUSION: A 4Kscore test cut-off of 7.5% allowed a significant biopsy reduction, while maintaining high sensitivity and NPV for detecting and ruling out aggressive prostate cancer.
引用
- Bhattu AS, Zappala SM, Parekh DJ, et al. A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer. Urology. 2020. PMID: 33217456. doi:10.1016/j.urology.2020.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。